Trial Profile
Phase 1/2 Study of Chemoimmunotherapy With Toll-like Receptor 8 Agonist Motolimod (VTX-2337) + Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin is Indicated
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Motolimod (Primary) ; Doxorubicin
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2021 Status changed from active, no longer recruiting to completed.
- 16 Feb 2021 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 23 Aug 2019 Planned End Date changed from 1 Mar 2019 to 1 Jun 2020.